Novo Nordisk: Stifel maintains buy rating

(CercleFinance.com) - Stifel maintains its buy rating on Novo Nordisk shares, along with its target price of 1280 DKK.


"Unsurprisingly, obesity exposes Novo Nordisk as the leading player to some volatility in its share price, due to the various push and pulls that take place within and around this field," says the analyst for whom, in the space of a few hours, several pieces of news have generated "hopes and created concerns".

However, overall, Stifel sees more positives than negatives. The results of the semaglutide trial showed positive data even though comparison with its competitors is not always to its advantage.


Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.